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PPARs are members of the steroid hormone nuclear receptor superfamily and play an important role in regulating inﬂammation
as well as lipid metabolism. The PPAR subfamily has been deﬁned as PPARα,P P A R β/δ,a n dP P A R γ,e a c hw i t hd i ﬀerent ligands,
target genes, and biological roles. PPARs regulate the expression of target inﬂammatory genes through mechanisms involving
both transactivation and transrepression. The anti-inﬂammatory properties of PPAR agonists have led to the investigation of
PPAR functions in regulating autoimmune encephalomyelitis. This paper will summarize some of the general mechanisms by
which PPARs regulate inﬂammatory gene expression and focus on the recent advances of PPAR regulation of autoimmune
encephalomyelitis.
1.PeroxisomeProliferator-Activated
Receptors (PPARs)
The nuclear receptor superfamily integrates both inﬂam-
matory and metabolic signals to maintain homeostasis in
immune cells such as macrophages, dendritic cells, and
lymphocytes [1, 2]. PPARs are nuclear receptors activated
by fatty acids and control the expression of genes involved
in both lipid metabolism and inﬂammation. So far, there
are three isoforms that have been identiﬁed and cloned,
including PPAR-α,P P A R - β/δ,a n dP P A R - γ,a n dt h e ye x h i b i t
diﬀerent tissue distribution as well as diﬀerent ligand
speciﬁcities. PPARα was the founding member of the PPAR
subfamily and was ﬁrst cloned in rodents. It was shown to
be activated by a diverse class of rodent hepatocarcinogens
that causes proliferation of peroxisomes [3]. Subsequently,
two other family members were discovered, PPARβ/δ and
PPARγ [4, 5]. Natural ligands for the PPARs include native
and modiﬁed polyunsaturated fatty acids and eicosanoids
[6–8]. Additionally, the PPARs ha v eal a r g el i g a n d - b i n d i n g
pocket that can accommodate a diverse range of synthetic
ligands [9–11].
All PPARs have four main domains named A/B, C, D,
and E/F. The N-terminal A/B domain has a transcriptional
activating function (AF-1). The C domain, or DNA binding
domain (DBD), is formed by two zinc ﬁnger-like motifs that
can recognize a peroxisome proliferator response element
(PPRE) on target genes. PPREs are speciﬁc DNA sequences
of the repetition of a consensus hexanucleotide sequence
(AGGTCA), separated by one or two nucleotides. The D
domain is a hinge region that can modulate the DNA
binding ability and is involved in cofactor interaction. The
E/F domain is the ligand-binding domain (LBD), which is
responsible for the ligand binding and is involved in the
dimerization with the 9-cis retinoic acid receptor (RXR)
[12].
PPARs are expressed by several diﬀerent immune cells,
including macrophages [13–15], T cells [16–19], B cells
[20], and dendritic cells [21–23]. Other than regulation of
lipid metabolism, PPARs have also been shown to play an
important role in regulating immune responses and inﬂam-
mation, by programming inﬂammatory gene expression in
immune cells, including macrophages, dendritic cells, and
lymphocytes [8, 24, 25]. All three members of the PPAR2 PPAR Research
family have been shown to exert anti-inﬂammatory eﬀects
in vitro and in vivo. The anti-inﬂammatory eﬀects of PPAR
agonistshavebeenobservedinautoimmunediseases,includ-
ing multiple sclerosis (MS) and experimental autoimmune
encephalomyelitis(EAE).Althoughthe detailed mechanisms
by which PPARs regulate inﬂammatory responses and
autoimmune encephalomyelitis are still not well established,
recent studies have broadened our understanding on the
transcriptional regulation of inﬂammatory target genes by
PPARs and shed light on the mechanism of PPAR regulation
ofautoimmuneencephalomyelitis.Thepositiveregulationof
target gene transcription by PPARs was through direct bind-
ing to the PPRE on the promoter of target genes, whereas
negative regulation of target gene expression was mostly
indirect, through a mechanism termed transrepression [6,
26]. This paper will summarize some general mechanisms
by which PPARs regulate inﬂammatory gene expression
and focus on the recent advances of PPAR regulation of
autoimmune encephalomyelitis.
2.GeneralMechanisms ofPPARAction
2.1. Positive Regulation of Target Gene Expression. PPARs
can both positively and negatively regulate their target
gene expression. One of the mechanisms by which PPARs
exert their function is through binding to a PPRE as
a heterodimer with RXR in a ligand-dependent manner.
Ligand-dependent activation is linked to the recruitment of
coactivator complexes that modify chromatin structure and
facilitate assembly of the general transcriptional machinery
at the promoter [27, 28].
In the unliganded state, PPARs are associated with a
nuclear receptor corepressor. NCoR (nuclear receptor core-
pressor) isamong themost studiedcorepressors. Inaddition,
heat shock protein-90 and the hepatitis virus B X-associated
protein 2 have been shown to be associated with PPAR-
α, which negatively regulates subsequent gene activation
[29, 30]. Upon ligand activation, the PPARs undergo a
conformational change that results in the dissociation from
the corepressor, enabling the PPARs to bind nuclear recep-
tor coactivators. These coactivators then act to reorganize
the chromatin templates allowing the basal transcription
machinery to gain access to the promoter regions and
drive the transcription of target genes [24]. One example
of positive regulation of inﬂammatory gene expression in
autoimmune encephalomyelitis is the regulation of IL-4
gene by the PPARα agonist gemﬁbrozil. Gemﬁbrozil induced
immune deviation and protected mice from EAE. PPAR-α
wasshown toregulatetheIL-4andIL-5genesandbindtothe
IL-4 promoterinthe presence ofsteroid receptorcoactivator-
1 (SRC-1), suggesting transactivation of the IL-4 gene [31].
2.2. Negative Regulation of Target Gene Expression by Transre-
pression. The ligand-dependent gene repression by PPARs is
mediated throughan indirect regulatory mechanism, termed
ligand-dependent transrepression, which is distinguished
from active repression of target genes in that the repression
does not depend on the binding of PPARs to PPREs in target
gene promoters. The general mechanism of transrepression
involves protein-protein interactions between PPARs and
their target transcription factors or coregulatory complexes.
Transrepression is widely used to negatively regulate gene
expression but the detailed mechanism by which diﬀerent
nuclear receptors exert their speciﬁc transrepression varies
from receptor to receptor. It is diﬃcult to identify a uniﬁed
mechanism of repression by all PPARs, since signal, cell,
and/or promoter-speciﬁc mechanisms exist for all three
PPAR family members.
2.2.1. Tether Transcription Factors Away from Their Binding
Sites. One of the mechanisms by which PPARs transrepress
their target inﬂammatory gene expression is to tether
transcription factors away from their DNA binding sites
in the target gene promoter region, which in turn inhibits
gene transcription of the target inﬂammatory genes. This
process involves physical interaction between PPARs and
their target transcription factors. The inhibition of phorbol
ester-induced IL-2 expression by PPARγ was mediated by
this mechanism. PPARγ ligands, troglitazone and 15 deoxy
Delta (12, 14) prostaglandin J (2) (15d-PGJ2), inhibited IL-2
production and phytohemagglutinin-inducible proliferation
in human peripheral blood T cells in a dose-dependent
manner. The activated PPARγ physically associates with
the transcription factor, nuclear factor of activated T cells
(NFAT), regulating the IL-2 promoter by blocking NFAT
DNA binding and transcriptional activity. The ligand-
dependent binding of PPARγ to NFAT correlates with the
dissociation of NFAT from the IL-2 promoter [32].
2.2.2. SUMOylation-Dependent Pathway. Another impor-
tanttransrepression pathwayistheSUMOylation-dependent
pathway. SUMOylation-dependent targeting of a nuclear
receptor to corepressor complexes to prevent their signal-
dependentclearanceislikelytorepresenta generalmolecular
strategy for transrepression of proinﬂammatory target genes
[33, 34]. The SUMOylation-dependent pathway mediated
transrepression of inﬂammatory response genes was ﬁrst
identiﬁed for PPARγ and then extended to PPARα and two
additional members of the nuclear receptor family, LXRα
and LXRβ. In macrophages, the SUMOylation-dependent
pathway was initiated by ligand-induced SUMOylation of
the PPARγ ligand-binding domain. This modiﬁed PPARγ
in turn bound to NCoR complexes associated with the pro-
moters of target inﬂammatory genes, which were marked by
the presence of NCoR-HDAC3-TBL corepressor complexes.
These complexes prevented Ubc5 recruitment in response
to lipopolysaccharide (LPS) signals, which supposedly led to
the clearance of NCoR and HDAC3, and the switch from
repression to transcriptional activation. As a result, NCoR
complexes were not cleared from the promoter, and target
genes were maintained in a repressed state [33].
Collectively, recent studies have deﬁned some molecular
mechanisms bywhichPPARspositivelyornegativelyregulate
their target inﬂammatory gene expression. However, the
molecular mechanisms by which PPARs regulate autoim-
mune encephalomyelitis have not been well deﬁned. So far,PPAR Research 3
no study has been published demonstrating the detailed
molecular mechanism of negative regulation of PPAR in the
EAE model although Gocke et al. showed the molecular
pathwayofpositiveregulationofIL4andIL5genebyPPAR-α
inEAE.Morestudiesare neededinthefuturetoelucidatethe
detailed mechanisms by which PPARs regulate autoimmune
encephalomyelitis.
3.MS and EAE
MS is the leading cause of neurologic disability in the United
Statesinyoungadultsaftertrauma; thus,most patientssuﬀer
from the eﬀects of MS for most of their adult life. MS is
thought to be a T cell-mediated autoimmune disease of
the central nervous system (CNS) with a complex genetic
background. Although the precise etiology of MS is still
unknown, it is generally accepted that MS begins with the
formation of acute inﬂammatory lesions which are mediated
by autoreactive T cells and B cells. The demyelinating
plaques are dominated by activated T cells and macrophages
associated with oligodendrocyte and myelin destruction
(Figure 1).
CD4 T cells are at the center of MS pathogenesis and
are the focus of MS research, given their important role in
mediating disease. CD4 T cells diﬀerentiate into diﬀerent
types of T eﬀector cells in the periphery in response to
diﬀerent pathogenic microorganisms as a result of recogni-
tion of these organisms by the innate immune system. It
has been suggested for more than two decades that there
are two diﬀerent types of CD4 T helper cells, Th1 and
Th2 cells. The Th1 cell subset mainly produces IFN-γ,I L -
2 and GM-CSF, while the Th2 cell subset produces IL-4,
IL-5 and IL-13 [35–38]. Th1 cells have been implicated
in a variety of autoimmune diseases, including MS [39–
41]. Conversely, Th2 cells control infections by extracellular
microbes, and cytokines produced by Th2 cells mediate
helper T cell functions for antibody production and mediate
the immunopathology of allergic responses. Early studies
suggested that the IFN-γ producing Th1 CD4 T cells, which
were driven by IL-12, played an essential role in mediating
disease, while Th2 cytokines such as IL-4 were associated
with amelioration of EAE and remission in MS. More
recently, Th17 cells have been identiﬁed as a new CD4 T cell
lineage. In vivo, Th17 cells were driven by IL-23 although,
in vitro, they were induced by TGF-β and IL-6. Th17 cells
also have been shown to be critical in the development of
autoimmune diseases. Studies have been done to deﬁne the
roles of diﬀerent T cell subpopulations in MS pathogenesis
and focus on how to manipulate pathogenic Th1 and Th17
cells and related cytokines to suppress disease.
EAE is an inﬂammatory demyelinating disease mediated
by myelin-speciﬁc Th1 and Th17 CD4 lymphocytes. EAE is
characterized by relapsing paralysis, CNS inﬂammation, and
demyelination. It hasbeen used as a model forMS forseveral
decades, since it shares clinical and immunopathological
similarities to MS. EAE can be induced in mice by immu-
nization with various myelin proteins or peptides emulsiﬁed
in CFA or by the transfer of activated myelin-speciﬁc CD4
Th1 lymphocytes into naive recipients.
The anti-inﬂammatory properties of PPAR agonists have
led to the investigation of PPAR functions in regulating
autoimmuneencephalomyelitis,hopingtodevelopnew ther-
apeuticstrategies forMS. Many studieshave beenperformed
totesttheeﬀectsofdiﬀerentPPARagonistsinregulatingEAE
and have shown very promising results. Some of the targets
of PPARs in MS pathogenesis are shown in Figure 1.B a s e d
on these promising animal data, a PPAR agonist has been
tested in a clinical trial as an adjunctive treatment for MS
patients. In the next three sections, we are going to discuss
the regulation of autoimmune encephalomyelitis by PPARγ,
PPARα,a n dP P A R β/δ, respectively.
4.RegulationofAutoimmune
Encephalomyelitisby PPARγ
4.1. PPARγ Agonists Suppress EAE. Several PPAR-γ agonists
have beenshown toameliorate EAE. Troglitazone was shown
to ameliorate MOG 35-55-induced EAE in C57BL/6 mice,
and troglitazone treatment during the eﬀector phase is
more eﬀective than when it is given during the induction
phase [42]. Administration of another PPARγ agonist,
15d-PGJ2, before and at the onset of clinical signs of
EAE signiﬁcantly reduced the severity of disease in B10
PL mice. More importantly, culture of encephalitogenic
T cells with 15d-PGJ2 reduced their ability to adoptively
transfer EAE, suggesting that PPAR-γ ligands may regulate
T cell encephalitogenicity in vitro [43]. Furthermore, the
combination of 15d-PGJ2 and 9-cis-retinoic acid (RA), the
ligand forRXR,resultedinenhancedameliorationofdisease,
suggesting that combination of RXR-speciﬁc ligands and
PPARγ ligands may be highly eﬀective in the treatment
of autoimmune demyelinating diseases such as MS [44].
Similarly, in SJL/J mice, 15d-PGJ2 or Ciglitazone decreased
thedurationand clinicalseverityof activeimmunization and
adoptive transfer models of EAE [45]. Orally administered
pioglitazone was also shown to reduce the incidence and
severity of monophasic, chronic disease in C57BL/6 mice
and of relapsing disease in B10.PL mice. Pioglitazone also
reduced clinical signs when it was provided after disease
onset. The suppression of clinical signs was paralleled by
decreased lymphocyte inﬁltration, lessened demyelination,
reduced chemokine and cytokine expression, and increased
inhibitor of κB( I κB) expression in the brain [46]. Another
PPARγ aonist, rosiglitazone, when used to treat DCs, was
able to prevent EAE development in mice [47].
On the other hand, PPARγ antagonists exacerbated
EAE. Treatment with PPARγ antagonists, Bisphenol A
diglycidyl ether (BADGE), or 2-Chloro-5-nitro-N-(4-
pyridyl)benzamide (T0070907) increased the severity and
duration of EAE in C57BL/6 wild-type and PPARγ-deﬁcient
mice. The exacerbation of EAE was associated with an
augmentedneuralantigen-inducedTcellproliferation,IFNγ
production, and Th1 diﬀerentiation [48]. Furthermore,
BADGE and benzamide (T0070907) reversed the inhibition
of EAE by the PPARγ agonists, Ciglitazone and 15d-PGJ2,
in C57BL/6 wild-type and PPARγ+/− mice. The reversal
of EAE was associated with restoration of neural antigen-
induced T cell proliferation, IFNγ production, and Th14 PPAR Research
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Figure 1: Regulation of autoimmune encephalomyelitis by PPAR agonists. CD4 T cells diﬀerentiate into diﬀerent types of T eﬀector cells
in the periphery in response to diﬀerent pathogenic microorganisms as a result of recognition of these organisms by the innate immune
system. The IL-12-driven Th1 cell subset mainly produces IFN-γ, IL-2, and GM-CSF and plays an essential role in mediating disease. The
Th2 cell subset produces IL-4, IL-5, and IL-13, which are associated with amelioration of EAE and remission in MS. The IL-23-driven
Th17 cells have also been shown to be critical in the development of autoimmune diseases. PPAR agonists have been shown to suppress
autoimmuneencephalomyelitis by regulating the function of both immune cells and CNS-resident cells, including inhibiting Th1 and Th17
diﬀerentiation, promoting Th2 diﬀerentiation,inhibitinginﬂammatorycytokine production by microglia andastrocytes, andincreasing the
number of myelin-producing OLs. Increased expression is indicated by green arrow and decreased expression shown by red blockade.
diﬀerentiation inhibited by Ciglitazone and 15d-PGJ2
[49].
Together, these data demonstrated that PPARγ played an
important role in regulating autoimmune encephalomyelitis
in vivo and suggested that PPARγ agonists might be a
new therapeutic treatment for autoimmune demyelinating
diseases such as MS.
4.2.EAEinPPARγ-DeﬁcientMice. Itiscontroversialwhether
PPARγ agonists such as 15d-PGJ2 require PPARγ for
their anti-inﬂammatory function, because there are studies
showing PPARγ-independent mechanisms in the induction
of anti-inﬂammatory eﬀects by 15d-PGJ2 [50]. PPARγ-
deﬁcient heterozygous mice were used to demonstrate the
function of endogenous PPARγ in EAE. In the endogenous
state,thePPARsarelikelyoccupiedbytheirfattyacidligands,
which may be produced at sites of inﬂammation. PPARγ-
deﬁcientheterozygousmicedevelopedanexacerbatedcourse
of EAE with prolonged clinical signs compared to wild-
type littermates. The exacerbation was associated with an
increased expansion of CD4 and CD8 T cells and expression
of CD40 and MHC class II molecules in response to antigen,
conﬁrming PPARγ as a critical regulator of EAE and perhaps
MS [51].
4.3. Role of PPARγ in Regulating Immune Cells in EAE.
Since studies in vivo showed PPARγ agonists inhibited
CNS inﬂammation and demyelination in EAE, studies were
done to elucidate the potential therapeutic mechanisms.
Troglitazone has been shown to attenuate the inﬂammation
and decreased the clinical signs through the attenuation
of proinﬂammatory cytokine gene expression in the spinal
cord [42]. In addition to this, additional studies have been
published to show the diﬀerent eﬀects of PPARγ agonists on
immune cells and CNS resident cells in EAE as described
below.
4.3.1. Antigen-Presenting Cells. PPARγ agonists were shown
to regulate the function of antigen-presenting cells, includ-
ing monocyte/macrophages and dendritic cells. 15d-PGJ2
was shown to inhibit phorbol ester-induced nitric oxide
(NO), TNF-α, IL-1, and IL-6 production by cells of thePPAR Research 5
monocyte/macrophage lineage, in part by antagonizing the
activities of transcription factors such as AP-1 and NF-κB
[14,15].AnotherPPARγ agonist,rosiglitazone,wasshown to
interfere with NF-κBa c t i v a t i o ni nm u r i n eD C s .A sar e s u l t ,
treated DCs showed impaired maturation and a reduced
capacity to activate antigen-speciﬁc T cells and were able to
prevent EAE development in mice [47].
4.3.2. T Cells. Since MS and EAE are suspected T cell-
mediatedautoimmunediseases,studieshavebeenconducted
to determine how PPARs regulate T cell function. 15d-
PGJ2 was shown to inhibit the proliferation of Ag-speciﬁc
T cells from myelin basic protein Ac1-11 TCR-transgenic
mice and suppress IFN-γ, IL-10, and IL-4 production by
lymphocytes. Similarly, the disease inhibition with 15d-PGJ2
or Ciglitazone in SJL/J mice was associated with a decrease
in IL-12 production and diﬀerentiation of neural antigen-
speciﬁc Th1 cells. Treatment of activated T cells with PPARγ
agonists in vitro inhibited IL-12-induced activation of the
JAK-STAT signaling pathway and Th1 diﬀerentiation [45].
Orally administered pioglitazone was also shown to reduce
the antigen-dependent IFN-γ production from EAE-derived
T cells [46].
In addition to pathogenic Th1 cells, Th17 cells have also
been shown to be pathogenic in MS and EAE. One recent
study identiﬁed PPARγ as a key negative regulator of human
and mouse Th17 diﬀerentiation. PPARγ activation in CD4
T cells selectively suppressed Th17 diﬀerentiation through
inhibition ofTGF-β/IL-6 inducedRORγt expression, but not
diﬀerentiation into Th1, Th2, or regulatory T cells. More
importantly, human CD4 T cells from healthy controls and
MS patients were strongly susceptible to PPARγ-mediated
suppression of Th17 diﬀerentiation, suggesting that PPARγ
is a promising molecular target for speciﬁc immunointer-
vention in Th17-mediated autoimmune diseases such as MS
[52].
4.4. Role of PPARγ in CNS-Resident Cells in EAE. Other
than regulating immune responses, PPARγ agonists were
also shown to regulate the functions of CNS-resident cells,
including microglia and astrocytes. It has been shown that
PPARγ agonists modulate EAE, at least in part, by inhibit-
ing the activation and cytokine production of microglia
and astrocytes. 15d-PGJ2 together with 9-cis retinoic acid
potently inhibited microglial cell activation and inhibit
EAE development in mice [53]. Three TZDs, rosiglitazone,
pioglitazone, ciglitazone, and 15d-PGJ2, were all eﬀective
in inhibiting production of NO, the proinﬂammatory
cytokines TNF-α,I L - 1 β, and IL-6, and the chemokine MCP-
1 from microglia and astrocytes [54, 55]. 15d-PGJ2 and
rosiglitazone inhibited the induction of IL-12p40, IL-12p70
(p35/p40), IL-23 (p19/p40), and IL-27p28 proteins by LPS-
stimulatedprimary microglia.15d-PGJ2 potentlysuppressed
IL-12p40, IL-23, and IL-27p28 production by primary
astrocytes, whereas rosiglitazone suppressed IL-23 and IL-
27p28, but not IL-12p40 in these cells [56]. These eﬀects on
CNS-resident cells might contribute to the suppression of
EAE by PPARγ agonists.
4.5. PPARγ Agonists and MS. PPARγ agonist pioglitazone
was tested as an add-on therapy with interferon-β in a small
cohort of relapsing remitting MS (RRMS) patients. RRMS
patients taking IFNβ-1α were randomized to treatment with
pioglitazone (30mg daily, p.o.) or placebo and monitored
clinically by EDSS and by MRI for 1 year. After 1 year, there
were no signiﬁcant diﬀerences in clinical signs as assessed by
EDSS; however, MRI showed a signiﬁcant reduction in gray
matter atrophy and a trend for reduced lesion burden in the
treatment group.Thesedatasuggestedsomebeneﬁcialeﬀects
for RRMS patients, and further trials need to be performed
to establish clinical eﬃcacy [57].
PPARγ involvement in autoimmune encephalomyelitis
was also implicated by a population-based study in MS
patients. The Ala allele of the PPARγ Pro12Ala polymor-
phism was strongly associated with delayed disease onset
(44.1±5.3 years versus34.5±4.2y ear s ;P = .006).This study
demonstrated that the Pro12Ala polymorphism resulting
in an amino acid exchange in the N-terminal sequence of
PPARγ may inﬂuence the onset of MS [58].
In summary, data from EAE studies showed that PPARγ
agonists were able to suppress disease severity by regulating
the functions of both immune cells and CNS-resident
cells (Table 1), supporting PPARγ agonists as an eﬀective
treatment of autoimmune demyelinating diseases such as
MS. Small-scale clinical data further conﬁrmed that the
PPARγ agonist pioglitazone maybe beneﬁcial for RRMS
patients. More clinical studies are needed to further establish
clinical eﬃcacy.
5.RegulationofAutoimmune
Encephalomyelitisby PPARα
PPARα is expressed in diﬀerent immune cells, including
monocytes/macrophages, T cells, and B cells and plays an
important role in regulating inﬂammation and cytokine
production. PPARα agonists have also been tested in the
treatment of EAE and shown to be protective [24]. However,
recent studies showed, other than sharing the common anti-
inﬂammatory eﬀects of all three PPAR subtypes, PPARα had
speciﬁc eﬀects in inducing immune deviation in EAE. This
speciﬁc regulation of immune deviation made these PPARα
agonists very attractive candidates to be used therapeutically
in treating Th1-mediated autoimmune diseases, including
MS, in addition to their excellent track history as oral agents
usedtotreathypertriglyceridemia.Herewearegoingtofocus
on several recent studies demonstrating PPARα regulation of
immune deviation, gender diﬀerences, and its role in CNS-
resident cells (Table 2).
5.1. Immune Deviation Induced by PPARα Agonists
5.1.1. Immune Deviation. Th1 and Th2 cells are two distinct
CD4 T cell lineages, and they play diﬀerent roles in
autoimmune diseases, including MS and EAE. Autoimmune
diseases can be divided into those mediated by Thl cells
withprimarilyinﬂammatory manifestations andthosemedi-
ated by Th2 cells whose manifestations are secondary to6 PPAR Research
Table 1: The eﬀects of PPARγ agonists in EAE.
Agonists (concentration) Eﬀects on immune cells Eﬀects on CNS cells References
15d-PGJ2 (100υg/kg/day to
1mg/kg/day)
Suppresses T cell
proliferation Suppresses
IFN-γ,I L 1 2a n dI L 4
production.
Inhibits Th1
diﬀerentiation.
Inhibits CD40 expression
on microglial cells.
Inhibits production of NO,
TNF-α,I L - 1 β,a n dI L - 6 ,
and MCP-1, and IL12,
IL23, IL27 expression from
microglia and astrocytes.
Diab et al. [43, 44],
Natarajan and Bright [45],
Drew et al. [53], Storer et
al. [54, 55], Xu and Drew
[56]
Pioglitazone
(5–10mg/kg/day)
Reduces T-cell activation.
Suppresses Th17
diﬀerentiation in CD4 cells.
Inhibit RORγt expression
in T cells.
Inhibits production of NO,
TNF-α,I L - 1 β,a n dI L - 6 ,
and MCP-1 from microglia
and astrocytes.
Feinstein et al. [46], Klotz
et al. [52], Drew et al. [53],
Storer et al. [54, 55]
Rosiglitazone
(5–10mg/kg/day)
Inhibits NF-Kb Activation
in DC.
Inhibits production of NO,
TNF-α,I L - 1 β,a n dI L - 6 ,
and MCP-1 from microglia
and astrocytes.
Inhibits IL12, IL23 and
IL27 expression in
microglia.
Inhibits IL23 and IL27
expression in astrocytes.
Iruretagoyena et al. [47],
Feinstein et al. [46], Drew
et al. [53], Storer et al.
[54, 55], Xu and Drew [56]
Ciglitazone
(50–100ug/kg/day)
Inhibit IL-12 production in
macrophages and Th1
diﬀerentiation.
Inhibit IL-12 production in
microglial cells.
Inhibits production of NO,
TNF-α,I L - 1 β,a n dI L - 6 ,
and MCP-1 from microglia
and astrocytes.
Natarajan and Bright [45],
Drew et al. [53], Storer et
al. [54, 55]
Troglitazone
(50–100mg/kg/day)
Suppresses
TNF-α expression in spinal
cord.
Niino et al. [42]
autoantibody containing immune complexes [66]. Immune
deviation was a term used to characterize an immune
response where Th2 cells predominate, and one approach to
the immunotherapy of inﬂammatory autoimmune disease,
including MS, was the antigen-speciﬁc deviation of an
immune response dominated by a Th1 response to a Th2
response.
5.1.2. PPARα Agonists Ameliorate EAE by Inducing Immune
Deviation. The PPARα agonist gemﬁbrozil was shown to
regulate immune responses by promoting the deviation of
immune responses dominated by a pathogenic Th1 response
to a nonpathogenic Th2 response [31, 60, 67]. Lovett-Racke
et al. demonstrated that PPARα agonists induced a shift in
cytokine production from Th1 cytokines to Th2 cytokines
in both mouse and human T cells and protected mice
from EAE. PPARα agonists increased the production of the
Th2 cytokine, IL-4, and suppressed proliferation by TCR
transgenic T cells speciﬁc forthemyelin basic protein Ac1-11
peptide. Oral administration of PPARα agonists gemﬁbrozil
and fenoﬁbrate inhibited the clinical signs of EAE. More
importantly, the PPARα agonist gemﬁbrozil shifted the
cytokine secretion of human T cell lines from IFNγ secretion
to IL-4 secretion [59]. Gocke et al. studied the molecular
mechanisms by which PPARα agonists induce immune
deviation and protect mice from EAE. They demonstrated
that PPARα agonists directly activated Th2 cytokine IL-4
gene expression by directly binding to the IL-4 promoter
region. Gemﬁbrozil treatment increased Th2 transcription
factor GATA-3 expression and decreased Th1 transcription
factor T-bet expression in vitro and directly ex vivo. For the
ﬁrst time,theyshowed that PPARαr e g u l a t e dt h eI L - 4a n dI L -
5 genes and bound the IL-4 promoter in the presence of the
steroid receptor coactivator-1 [31].
5.1.3. Is the Eﬀect Receptor Dependent or Not? Gocke et al.
showed that the protective eﬀects of PPARα agonists in EAE
occurred in a receptor-dependent manner [31]. Dasgupta
et al. observed similar eﬀects with the PPARα agonist
Gemﬁbrozil in mice, including switching of a Th1 proﬁle
to a Th2 proﬁle, inhibiting T-bet expression, stimulating
GATA3 expression, and inhibiting the encephalitogenicity of
antigen-primed T cells. However, they suggested the switch
of immune response from a Th1 to a Th2 proﬁle by PPARα
agonists was receptor independent, as the drug was equally
eﬀective in treating EAE in PPARα-deﬁcient and well as
w i l d - t y p em i c e[ 60]. Similarly, Cunard et al. showed that
treatment with WY14,643 and other ﬁbrates led to marked
increases in supernatant concentrations of IL-4. They also
showedthatthiseﬀectonIL4productionwaslargelythroughPPAR Research 7
Table 2: The eﬀects of PPARα agonists in EAE.
Agonists (concentration) Eﬀects on immune cells Eﬀects on CNS cells References
Gemﬁbrozil (500ug/day)
Suppress lymphocyte
proliferation.
Increase IL4 production in
T cells.
Inhibit IFNγ production.
Inhibit the
encephalitogenicity of
MBP-primed T cells.
Switch the immune
response from a Th1 to a
Th2 proﬁle.
Increase GATA-3
expression and decrease
T-bet expression.
Regulate the IL-4 and IL-5
genes.
Reduce NO production by
microglia.
Inhibit IL-1β and IL-6
production by astrocytes.
Lovett-Racke [59],
Dasgupta et al. [60], Gocke
et al. [31]
Fenoﬁbrate Suppress lymphocyte
proliferation
Inhibit NO production by
microglial cells and
astrocytes.
Inhibit TNF-α expression,
IL-1β and IL-6 production
by astrocytes.
Inhibit NF-κBb i n d i n g
activity in astrocytes.
Repress IL-12p40,
IL-12p70, IL-23 and
IL-27p28 production by
microglia.
Lovett-Racke [59], Xu et al.
[61, 62]
Ciproﬁbrate
Suppress lymphocyte
proliferation.
Increase IL4 production in
T cells.
Inhibit IL-1β and IL-6
production by astrocytes
Lovett-Racke [59], Xu et al.
[62]
WY 14643 Increase IL4 production in
splenocytes
Inhibit NO production by
astrocytes.
Inhibit TNF-α expression,
IL-1β and IL-6 production
by astrocytes.
Xu et al. [62], Cunard et al.
[18, 19]
aP P A R α-independent mechanism, since WY14,643 induced
IL-4 expression in splenocytes from PPARα-deﬁcient mice
[19]. Further studies are needed to elucidate the receptor
dependency of PPARα agonists.
5.2. PPARα and Gender Diﬀerences. PPARα could be one
of the genes mediating gender diﬀerences in EAE. PPARα
expression in T cells is higher in male mice compared to
female mice, and this expression is reduced by castration
and increased by α-DHT treatment. The deﬁciency of
PPARα gene expression resulted in higher IFN-γ and TNFα
production by T cells in male mice. Male but not female
PPARα-deﬁcient mice developed more severe EAE that was
restricted to the acute phase of disease. These ﬁndings
provide a molecular basis for why males may be less prone
to developing Th1-mediated autoimmunity [67].
Women are more susceptible than men to develop
autoimmune diseases, including MS. In MS, twice as many
women as men develop the disease. This may be related to
the fact that women have more robust immune responses
than men although the exact mechanism is not understood
[68] .As t u d ys h o w e dw o m e nt ob em o r ep r o n et h a nm e n
to develop Th1-polarized responses directed against myelin
antigens during MS [69]. Whether PPARα is responsible for
the gender diﬀerences in MS susceptibility remains to be
determined.
5.3. PPARα Regulation of CNS-Resident Cells in EAE. More-
over, PPARα agonists were also shown to regulate CNS-
resident cells and the protective eﬀects of PPARα agonists in
EAEwereinpartthrougheﬀectsonCNScells.Microgliacells
are resident CNS cells that may serve as antigen-presenting
cells. Activated microglia exhibit increased pathogenic
cytokine production and increased synthesis of NO, which
may contribute to axonal degradation in MS. Xu et al.
showed that PPARα agonists inhibited microglia production
of NO, IL-1β,a n dT N F - α, which were potentially toxic
to cells including myelin-producing oligodendrocytes. In8 PPAR Research
Table 3: The eﬀects of PPARβ/δ agonistsin EAE.
Agonists (concentration) Eﬀects on immune cells Eﬀects on CNS cells References
GW0742 (10mg/kg/day)
Reduce astroglial and
microglial inﬂammatory
activation and IL-1β level
in brain.
Increase the number of
myelin-producing OLs.
Increase noggin protein
expression in both OPCs
and enriched astrocyte
cultures.
Polak et al. [63], Simonini
et al. [64]
GW501516
(25–100ug/day)
Inhibit the expression of
IFN-γ, IL-17, T-bet, IL-12
and IL-23.
Increase the expression of
IL-4 and IL-10.
Kanakasabai et al. [65]
L165041 (25–100ug/day)
Inhibit the expression of
IFN-γ, IL-17, T-bet, IL-12
and IL-23.
Increase the expression of
IL-4 and IL-10.
Kanakasabai et al. [65]
addition, these agonists inhibit microglial production of
Th1- and Th17-promoting cytokines, IL-12 and IL-23 [61].
PPARα agonists also suppressed microglia production of
MCP-1, a chemokine that plays an important role in
modulating monocyte inﬁltration into the CNS in MS [70].
Similar eﬀectswere observed in LPS-stimulated astrocytes. A
combination of 9-cis RA and the PPARα agonists fenoﬁbrate
orgemﬁbrozilcooperativelyinhibited NO,TNF-α,IL -1β,I L -
6, and MCP-1 production by these cells [62]. Thus, PPARα
agonists could also modify cytokine expression in the CNS
during inﬂammation such as that observed in EAE or MS.
6.RegulationofAutoimmune
Encephalomyelitisby PPARβ/δ
PPARβ/δ is the predominant PPAR isotype in brain. How-
ever, the exact functions of PPARβ/δ are not yet well under-
stood, but it is likely to play a role in cell proliferation [71],
diﬀerentiation, survival, lipid metabolism, and development
[72, 73].
6.1. PPAR-β/δ-Speciﬁc Agonists and EAE. Ap r o t e c t i v ee ﬀect
inEAEwasreportedforaPPAR-β/δ-speciﬁc agonist,andthis
protection was suggested to be due to a reduction in glial
inﬂammation. Polak et al. showed that oral administration
oftheselectivePPARδ agonistGW0742reducedclinicalsigns
in actively immunized C57BL/6 mice, especially when it was
administered during disease progression [63].The protective
eﬀect of GW0742 was receptor dependent, since no ame-
lioration of EAE clinical scores was observed in PPARδ-
deﬁcient mice [64]. RT-PCR analysis showed that GW0742
increasedexpressionofsomemyelingenes.GW0742reduced
astroglial and microglial inﬂammatory activation and IL-1β
levels in EAE brain.
Other than GW0742, two other PPARβ/δ agonists,
GW501516 and L165041 were shown to ameliorate
MOGp35-55-induced EAE in C57BL/6 mice by blocking
IFN-γ and IL-17 production by Th1 and Th17 cells [65].
GW 501516 was also tested for its capacity to protect from
antibody-mediated demyelination. However, GW 501516
did not protect against antibody-mediated demyelination
although it showed some anti-inﬂammatory activity [74].
The regulation of EAE by PPARβ was further con-
ﬁ r m e db yas t u d yi nS t e r o i dr e c e p t o rc o a c t i v a t o r - 3 - ( S R C -
3) deﬁcient mice. SRC-3 is a member of the p160 family of
coactivators that interact with nuclear receptors to enhance
their transactivation in a ligand-dependent manner. SRC-
3 deﬁciency signiﬁcantly inhibited the disease severity of
EAE. However, these eﬀects are not caused by inhibition of
peripheral T cell response, but by upregulation of PPARβ
in the CNS, which induced an alternative activation state
of microglia in SRC-3 deﬁcient mice. These alternatively
activated microglia inhibited CNS inﬂammation through
inhibition of proinﬂammatory cytokines and chemokines,
such as TNF-α,I F N - γ, CCL2, CCL3, CCL5, and CXCL10 as
well as upregulationof the anti-inﬂammatory cytokineIL-10
and opsonins [75].
6.2. PPARβ/δ Regulation of Immune Responses. Treatment
of T-cells with GW0742 either in vivo or in vitro did not
reduceTh1cytokineIFNγ production[63].However,astudy
showed that the PPARδ agonists, GW501516 and L165041,
ameliorated EAE by blocking IFNγ and IL-17 production by
Th1cells andTh17cellsandwas associatedwith adecreasein
IL-12 and IL-23 and an increase in IL-4 and IL-10 expression
in the CNS and lymphoid organs [65].
The PPARβ/δ regulation of immune cells was further
conﬁrmed by one recent study in PPARβ/δ-deﬁcient mice.
PPAR-β/δ-deﬁcient mice developed a severe inﬂammatoryPPAR Research 9
response during EAE characterized by a striking accumu-
lation of IFN-γ+ IL17A- and IFN-γ+I L - 1 7 A +C D 4 +c e l l s
in the spinal cord, which resulted from immune system
aberrations including enhanced Th cell expansion, cytokine
production, and T-bet expression and enhanced expression
of IL-12 family cytokines by myeloid cells. This data strongly
suggests that PPAR-δ serves as an important molecular brake
for the control of autoimmune inﬂammation [76]( Table 3).
6.3. PPARβ/δ and Oligodendrocyte (OL) Maturation. The
special feature of PPARδ function is that PPARδ agonists
are more eﬀective when administered during later stages
of disease and they increase myelin gene expression [63],
which suggested that they might aﬀect OL maturation.
Vittoria Simonini et al. demonstrated that PPARδ played a
role in OPC maturation. GW0742 was shown to increase
the number of myelin-producing OLs in OPCs, and this
was receptor dependent, since OLs were reduced in PPAR-
deﬁcient OPCs [64].
7.Conclusion
PPARs are lipid-activated transcription factors that have
emerged as key regulators of both lipid metabolism and
inﬂammation. They exert positive and negative controls over
the expression of a range of inﬂammatory genes. The anti-
inﬂammatory properties of PPARs make them attractive
targets for intervention in human autoimmune diseases,
including MS. A growing body of literature suggested that
PPAR agonists could be used therapeutically in autoimmune
diseases such as MS as a preliminary clinical study has sug-
gested. Further studies will be required to fully understand
the complicated mechanisms of PPAR regulation of immune
responses and autoimmune encephalomyelitis.
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